HHS awards $16.7M for COVID-19 testing platforms, bypassing competition

Contract Overview

Contract Amount: $16,670,000 ($16.7M)

Contractor: Flambeau Diagnostics LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2021-07-01

End Date: 2023-03-31

Contract Duration: 638 days

Daily Burn Rate: $26.1K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS

Place of Performance

Location: MONONA, DANE County, WISCONSIN, 53716

State: Wisconsin Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $16.7 million to FLAMBEAU DIAGNOSTICS LLC for work described as: RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS Key points: 1. Contract awarded on a sole-source basis, raising questions about price discovery and potential for overpayment. 2. Research and Development in Biotechnology sector, focusing on novel testing platforms. 3. Significant duration of 638 days suggests a substantial project scope. 4. No small business set-aside or subcontracting noted, potentially limiting broader economic impact. 5. Contract type is Firm Fixed Price, which can offer cost certainty but may not capture efficiencies. 6. Geographic focus on Wisconsin for the contractor. 7. High dollar value for a single award without competitive bidding warrants scrutiny.

Value Assessment

Rating: questionable

The contract value of $16.7 million for COVID-19 testing platforms is substantial. Without competitive bidding, it is difficult to benchmark the value for money. The firm fixed price structure provides cost certainty for the government, but the lack of competition means there's no market-driven validation of the pricing. Comparisons to similar R&D contracts for testing platforms would be necessary to assess if this price is reasonable, but such data is not readily available in this context.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning Flambeau Diagnostics LLC was the only vendor considered. The justification for this approach is not provided, but it implies that either no other vendors were capable of meeting the requirement or that the agency determined a competitive process was not feasible or necessary. The absence of competition limits the government's ability to explore alternative solutions and potentially secure better pricing through a bidding process.

Taxpayer Impact: Sole-source awards mean taxpayers do not benefit from the price reductions typically achieved through competitive bidding. This can lead to higher costs for government programs and potentially less efficient allocation of public funds.

Public Impact

The primary beneficiaries are likely the researchers and developers at Flambeau Diagnostics LLC, who will receive funding for their work. The services delivered are the development and provision of saliva-based COVID-19 testing platforms. The geographic impact is primarily focused on Wisconsin, where the contractor is located. Workforce implications could include job creation or retention within the biotechnology sector at the contractor's facility.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition for a significant award raises concerns about potential overpricing and missed opportunities for innovation.
Sole-source justification is not provided, making it difficult to assess the necessity of this procurement approach.
Limited transparency regarding the selection process and the specific capabilities of the chosen contractor.
No indication of small business involvement, potentially excluding smaller innovative firms from participating.

Positive Signals

The contract supports the development of critical COVID-19 testing technology, addressing a public health need.
Firm Fixed Price contract provides budget certainty for the government.
The award is directed towards a specific research and development area within biotechnology.

Sector Analysis

The contract falls within the Research and Development in Biotechnology sector, specifically focusing on diagnostic testing. This sector is characterized by innovation and high upfront investment. The market for COVID-19 testing has been dynamic, with significant government investment. Comparable spending benchmarks for R&D in novel diagnostic platforms can vary widely based on technological complexity and development stage. The $16.7 million award is a significant investment for a single platform development.

Small Business Impact

This contract does not appear to include any small business set-aside provisions, nor is there information suggesting subcontracting opportunities for small businesses. The sole-source nature of the award further limits the potential for small business participation. This approach may not leverage the agility and innovation often found in the small business ecosystem within the biotechnology sector.

Oversight & Accountability

Oversight mechanisms for this contract would typically involve the contracting officer and program managers within the National Institutes of Health (NIH). Accountability measures would be tied to the delivery of milestones and final product as defined in the contract. Transparency is limited due to the sole-source nature and lack of publicly available justification. Inspector General jurisdiction would apply to potential fraud, waste, or abuse.

Related Government Programs

COVID-19 Testing Development Programs
Biotechnology Research Grants
National Institutes of Health (NIH) Contracts
Diagnostic Platform Development

Risk Flags

Sole-source award without clear justification.
Lack of competitive bidding may lead to suboptimal pricing.
Potential for technical or regulatory hurdles in developing new testing platforms.
Evolving market dynamics for COVID-19 testing.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $16.7 million to FLAMBEAU DIAGNOSTICS LLC. RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS

Who is the contractor on this award?

The obligated recipient is FLAMBEAU DIAGNOSTICS LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $16.7 million.

What is the period of performance?

Start: 2021-07-01. End: 2023-03-31.

What was the specific justification for awarding this contract on a sole-source basis?

The provided data does not include the specific justification for the sole-source award. Typically, sole-source contracts are justified when only one responsible source is available or capable of meeting the agency's needs, or in cases of urgent and compelling need where competition is not feasible. For a contract of this magnitude in the R&D sector, agencies often cite unique capabilities, proprietary technology, or the need for continuity with prior research. Without the official justification document, it is impossible to definitively state the reason, but it likely relates to Flambeau Diagnostics LLC's unique qualifications or the specific nature of the required research and development for the saliva-based testing platform.

How does the $16.7 million contract value compare to similar R&D contracts for COVID-19 testing platforms?

Directly comparing the $16.7 million value without more specific details about the scope of work, technological maturity, and duration of similar contracts is challenging. The COVID-19 testing market saw a wide range of investments, from rapid development of existing technologies to foundational research for novel platforms. Contracts for developing entirely new diagnostic platforms, especially those requiring extensive research and validation like a saliva-based system, can command significant funding. However, the absence of competition for this specific award makes a direct value-for-money assessment difficult. Benchmarking would ideally involve analyzing other NIH or HHS awards for similar R&D efforts, considering factors like the number of bidders, final award prices, and project timelines to gauge if $16.7 million represents a competitive market rate for this type of innovation.

What are the key performance indicators (KPIs) or milestones associated with this contract?

The provided data does not specify the key performance indicators (KPIs) or milestones for this contract. Typically, for a Research and Development contract of this nature, milestones would be tied to the successful completion of specific research phases, development of prototypes, validation testing results, and potentially regulatory submission readiness. The Firm Fixed Price (FFP) contract structure implies that the contractor is responsible for delivering the defined scope of work within the agreed-upon price. The contracting officer and program managers at NIH would monitor progress against these milestones to ensure the government receives the intended value and that the project stays on track towards developing the saliva-based COVID-19 testing platforms.

What is the track record of Flambeau Diagnostics LLC in securing federal contracts, particularly in R&D?

Information regarding Flambeau Diagnostics LLC's broader track record in securing federal contracts is not detailed in the provided data. This specific award represents a significant sum ($16.7 million) for a sole-source R&D effort. To assess their track record, one would need to examine historical contract awards to this entity, looking at the types of contracts, agencies involved, performance history, and whether they have successfully completed similar R&D projects. A lack of extensive federal contracting history might increase perceived risk, while a strong history of successful R&D awards could provide confidence in their ability to deliver on this contract's objectives.

What are the potential risks associated with developing a new saliva-based COVID-19 testing platform under this contract?

Developing a new saliva-based COVID-19 testing platform carries several inherent risks. Technical risks include challenges in achieving the required sensitivity and specificity, ensuring stability of the sample and assay, and scaling up production. Regulatory risks involve navigating the approval process with agencies like the FDA, which can be lengthy and uncertain. Market risks exist as the demand for COVID-19 testing evolves, potentially shifting towards different technologies or becoming less prevalent. Furthermore, the sole-source nature of this contract introduces program risks if the chosen technology or approach proves less effective or efficient than potential alternatives that might have emerged from a competitive process. The long duration (638 days) also implies a complex development cycle where unforeseen issues could arise.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 4647 TONYAWATHA TRL, MONONA, WI, 53716

Business Categories: Category Business, Limited Liability Corporation, Partnership or Limited Liability Partnership, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $22,570,000

Exercised Options: $16,670,000

Current Obligation: $16,670,000

Actual Outlays: $16,670,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline